Quest Diagnostics Incorporated (DGX) has seen significant investor interest shown by the buying and selling shares. Advisors Capital Management, AQR Capital Management, Ascent Group, and Fred Alger Management have increased their holdings in the company. In contrast, Parkman Healthcare Partners, Cinctive Capital Management, Adage Capital Partners have sold their DGX shares. Furthermore, DGX shares have been purchased by Royal Bank of Canada and Alliancebernstein, whereas Advisors Asset Management has sold a portion of its DGX shares. Shining light on product development and partnerships, DGX has expanded its services with the launch of a nationwide pharmacogenomic test for precision medicine and a joint venture with Corewell Health in Michigan. In terms of financial performance, their revenue growth has been strong, leading to their uplifting outlook, despite some threats posed by tariffs and the Medicare Act. Also, DGX continues to deliver on its growth strategy, reflected in the 25.6% rally of its stock in a year. Innovation continues to play a key role, with DGX joining forces with Google Cloud to leverage Generative AI and streamline customer experience. Furthermore, the FDA grants breakthrough device designation for DGX's Haystack MRD Circulating Tumor DNA Test.
Quest Diagnostics DGX News Analytics from Mon, 27 Jan 2025 08:00:00 GMT to Sat, 13 Sep 2025 11:57:53 GMT - Rating 5 - Innovation 3 - Information 7 - Rumor 2
